tradingkey.logo
搜索

Telomir Pharmaceuticals Inc

TELO
添加自选
1.260USD
-0.010-0.79%
收盘 05/15, 16:00美东报价延迟15分钟
86.66M总市值
亏损市盈率 TTM

Telomir Pharmaceuticals Inc

1.260
-0.010-0.79%
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-0.79%

5天

-3.08%

1月

-5.97%

6月

-6.67%

今年开始到现在

-5.26%

1年

-49.60%

TradingKey Telomir Pharmaceuticals Inc股票评分

单位: USD 更新时间: 2026-05-15

操作建议

Telomir Pharmaceuticals Inc当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在药品行业排名119/155位。机构持股占比非常高,近一月多位分析师给出公司评级为。最高目标价15.50。中期看,股价处于上升通道。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Telomir Pharmaceuticals Inc评分

相关信息

行业排名
119 / 155
全市场排名
474 / 4482
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Telomir Pharmaceuticals Inc亮点

亮点风险
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
估值合理
公司最新PE估值-4.43,处于3年历史合理位
机构加仓
最新机构持股3.42M股,环比增加12.50%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值1.38K

分析师目标

根据 0 位分析师
--
评级
15.500
目标均价
+1120.47%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Telomir Pharmaceuticals Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Telomir Pharmaceuticals Inc简介

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
公司代码TELO
公司Telomir Pharmaceuticals Inc
CEOAminov (Erez)
网址https://telomirpharma.com/
KeyAI